According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
Separately, BidaskClub cut NanoString Technologies from a buy rating to a hold rating in a research note on Tuesday, August 6th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $24.60.
Shares of NSTG opened at $28.25 on Friday. The stock has a 50-day simple moving average of $29.05 and a 200-day simple moving average of $26.60. The company has a debt-to-equity ratio of 1.27, a quick ratio of 4.76 and a current ratio of 5.21. The stock has a market capitalization of $942.10 million, a PE ratio of -10.16 and a beta of 1.08. NanoString Technologies has a 1 year low of $13.26 and a 1 year high of $34.78.
NanoString Technologies (NASDAQ:NSTG) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.02). The company had revenue of $30.35 million during the quarter, compared to analysts’ expectations of $29.00 million. NanoString Technologies had a negative net margin of 68.16% and a negative return on equity of 118.03%. Analysts predict that NanoString Technologies will post -2.35 EPS for the current year.
In other news, CEO R Bradley Gray sold 40,000 shares of NanoString Technologies stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $24.84, for a total value of $993,600.00. Following the completion of the transaction, the chief executive officer now owns 89,905 shares in the company, valued at approximately $2,233,240.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David W. Ghesquiere sold 6,954 shares of NanoString Technologies stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $29.41, for a total value of $204,517.14. Following the completion of the transaction, the senior vice president now owns 44,868 shares of the company’s stock, valued at approximately $1,319,567.88. The disclosure for this sale can be found here. Insiders sold a total of 147,912 shares of company stock valued at $4,045,899 in the last quarter. Company insiders own 5.10% of the company’s stock.
A number of hedge funds have recently bought and sold shares of NSTG. James Investment Research Inc. purchased a new stake in NanoString Technologies during the second quarter worth approximately $25,000. Truvestments Capital LLC acquired a new position in NanoString Technologies during the second quarter worth approximately $74,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in NanoString Technologies during the second quarter worth approximately $75,000. Pearl River Capital LLC acquired a new position in NanoString Technologies during the first quarter worth approximately $76,000. Finally, Mizuho Securities Co. Ltd. acquired a new position in NanoString Technologies during the second quarter worth approximately $91,000.
NanoString Technologies Company Profile
NanoString Technologies, Inc provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.
See Also: Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.